Pediatric Brain Tumor Consortium

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Pediatric Brain Tumor Consortium sits in the top decile of US sponsors by registered trial count (#583 of 15,742 sponsors by registered trial count).

27 total trials none currently recruiting 12 completed early-phase tilt top decile by trial count

Pediatric Brain Tumor Consortium: 27 sponsored US clinical trials, none currently recruiting.

Pediatric Brain Tumor Consortium sponsors 27 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 12 completed. 0 of these trials are in Phase 3-4 (later-stage) and 24 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Brain and Central Nervous System Tumors, with 4 trials.

Top-decile sponsor footprint

Pediatric Brain Tumor Consortium ranks in the top decile of sponsors by registered trial count (#583 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

12 of 24 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (50.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

27 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 2

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

NCT04743661

ACTIVE NOT RECRUITING Phase 1

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

NCT04201457

ACTIVE NOT RECRUITING Phase 1

Phase I Study of APX005M in Pediatric Central Nervous System Tumors

NCT03389802

TERMINATED

Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors

NCT05934630

COMPLETED Phase 1

INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas

NCT04295759

TERMINATED Phase 1

Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery

NCT03904862

COMPLETED Phase 1

Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors

NCT03387020

COMPLETED Phase 1

Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma

NCT02717455

TERMINATED Phase 1

Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

NCT02255461

TERMINATED Phase 2

Peginterferon Alfa-2b in Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By Surgery

NCT01964300

TERMINATED Phase 1

Oncolytic HSV-1716 in Treating Younger Patients With Refractory or Recurrent High Grade Glioma That Can Be Removed By Surgery

NCT02031965

COMPLETED Phase 1

p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors

NCT01975116

TERMINATED Phase 2

Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors

NCT01836549

COMPLETED Phase 1

PTC299 in Treating Young Patients With Refractory or Recurrent Primary Central Nervous System Tumors

NCT01158300

TERMINATED Phase 1

MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer

NCT00572182

COMPLETED Phase 1

Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors

NCT00503724

COMPLETED Phase 1

Capecitabine and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Nonmetastatic Brain Stem Glioma or High-Grade Glioma

NCT00357253

TERMINATED Phase 1

Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors

NCT00112619

COMPLETED Phase 1

VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors

NCT00098761

TERMINATED Phase 1

TP-38 Toxin in Treating Young Patients With Recurrent or Progressive Supratentorial High-Grade Glioma

NCT00074334

TERMINATED Phase 1

Carmustine Implants and O(6)-Benzylguanine in Treating Children With Recurrent Malignant Glioma

NCT00045721

COMPLETED Phase 2

Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor

NCT00047177

COMPLETED Phase 1

SCH 66336 in Treating Children With Recurrent or Progressive Brain Tumors

NCT00015899

COMPLETED

Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children

NCT00010114

TERMINATED

Genetic Study of Brain Tumors in Young Children

NCT00010101

COMPLETED Phase 1

Busulfan in Treating Children and Adolescents With Refractory CNS Cancer

NCT00006246

TERMINATED Phase 1

SU5416 in Treating Children With Recurrent or Progressive Brain Tumors

NCT00006247

How the Pediatric Brain Tumor Consortium early-phase archive is shaped

27 indexed studies, none listed as recruiting (0% open); 12 completed (44%).

Phase mix: 0 late (III/IV) vs 24 early (I/II) (early-phase heavy).

Top condition: Brain and Central Nervous System Tumors (4 trials), 9 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Pediatric Brain Tumor Consortium: archived-pipeline peers nationwide

Peers matched on 27 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Pediatric Brain Tumor Consortium sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0102030 0%5%10%15%20% Total trials Recruiting share Pediatric Brain Tumor ConsortiumAkron Children's HospitalArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)AVEO PharmaceuticalsDompé Farmaceutici S.p.A10xBio22nd Century Group23andMe3-C Institute for Social Development
Pediatric Brain Tumor Consortium sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Pediatric Brain Tumor Consortium sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 27 archived trials

Sponsors with similar archive density (± trial count)

What to do with this Pediatric Brain Tumor Consortium page

27 registered trials is a research-attention snapshot, not an endorsement of Pediatric Brain Tumor Consortium or any single study.

  • None of Pediatric Brain Tumor Consortium's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Brain and Central Nervous System Tumors is the condition Pediatric Brain Tumor Consortium studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Brain and Central Nervous System Tumors trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Pediatric Brain Tumor Consortium pipeline card: 27 registered trials from official public datasets.Report a data error.